MyoKardia has reported positive data from the Phase Ia clinical trial of MYK-491 in healthy volunteers.

MYK-491 is an oral, small molecule myosin activator that has been designed to boost contractility of the heart (systolic function) with minimal effects on myocardial relaxation (diastolic function). The therapeutic was found to be well tolerated without any dose-limiting toxicities.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to the results, the drug candidate increased cardiac contractility by 5%-20% across various echocardiographic parameters at higher drug concentrations, with minimal impact on diastolic function.

MyoKardia executive vice-president and chief development officer June Lee said: “In developing MYK-491, we set out to target the underlying heart muscle proteins to increase contraction, with minimal impact on the heart’s ability to relax and fill with oxygenated blood between beats.

“Data from our Phase Ia study in healthy volunteers demonstrate that MYK-491 is achieving this desired effect, and these results have been confirmed by data from our Phase Ib study in patients with stable heart failure.”

The randomised, double-blind placebo-controlled, single-ascending dose Phase I trial evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MYK-491 in 64 healthy volunteers, compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the study, the most common adverse events (AE) observed was headaches, with no trend for increased AE frequency related to higher dose concentrations.

PK results demonstrated that the therapeutic may be amenable to once or twice-daily dosing.

MyoKardia presented these data at the European Society of Cardiology Heart Failure Congress in Athens, Greece.

The company is further studying MYK-491 in a Phase IIa multiple-ascending dose trial in patients with systolic heart failure. Top-line results from this trial are expected in the second half of this year.